Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$7.62 USD
+0.73 (10.60%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $7.53 -0.09 (-1.18%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.62 USD
+0.73 (10.60%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $7.53 -0.09 (-1.18%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Zacks News
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Strong execution across business segments, led by COVID-19 vaccinations and testing, drove Walgreens' (WBA) fiscal second-quarter top line.
Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
by Zacks Equity Research
Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.
All You Need to Know About Aligos Therapeutics, Inc. (ALGS) Rating Upgrade to Buy
by Zacks Equity Research
Aligos Therapeutics, Inc. (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Can Aligos Therapeutics, Inc. (ALGS) Climb 91% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Aligos Therapeutics, Inc. (ALGS) points to a 91.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Aligos (ALGS) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
Aligos (ALGS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy
by Zacks Equity Research
Aligos (ALGS) signs an exclusive research collaboration agreement with Merck to discover and develop an oligonucleotide therapy for NASH. Shares rise.